Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    20194698 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
Condition: Falciparum Malaria
Intervention: Drug: Primaquine
2 Completed Mass-Drug Administration to Reduce Malaria Transmission
Condition: Malaria, Falciparum
Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg);   Drug: Artesunate (day 1,2,3: 4 mg/kg);   Drug: Primaquine-base (day 3: 0.75 mg/kg);   Drug: placebo tablets
3 Completed Phase2a Primaquine Dose Escalation Study
Condition: Malaria
Interventions: Drug: dihydroartemisinin-piperaquine;   Drug: 0.125 mg/kg Primaquine;   Drug: 0.5 mg/kg Primaquine;   Drug: 0.25 mg/kg Primaquine;   Drug: 0.0625 mg/kg Primaquine

Indicates status has not been verified in more than two years